Literature DB >> 12974765

Over-expression of interleukin 10 in mucosal T cells of patients with active ulcerative colitis.

S Melgar1, M M-W Yeung, A Bas, G Forsberg, O Suhr, A Oberg, S Hammarstrom, A Danielsson, M-L Hammarstrom.   

Abstract

Ulcerative colitis (UC), a chronic inflammatory bowel disease, exhibits pronounced increase of T lymphocytes in the inflamed mucosa. To understand the role of intestinal T lymphocytes in the pathogenesis of UC their cytokine production in the mucosa was analysed. Intestinal T lymphocytes of UC, Crohn's disease and control patients were analysed for cytokine mRNA levels by real-time quantitative reverse transcription-polymerase chain reaction (RT-PCR) directly after isolation without in vitro stimulation. Frequencies of cytokine positive cells were determined in UC and control colon by immunomorphometry. T lymphocytes in normal colon expressed interleukin (IL)-2, interferon (IFN)-gamma, tumour necrosis factor (TNF)-alpha and transforming growth factor (TGF)-beta1, but not IL-4, IL-5 or IL-10. In UC, a highly significant increase in IL-10 mRNA levels in T lymphocytes and an increased frequency of IL-10 positive cells was seen in colon. IL-10 mRNA levels were also elevated in T lymphocytes of the non-inflamed ileum and correlated with disease activity at both locations. CD4+ T lymphocytes were the major source of IL-10 mRNA. IL-2, IFN-gamma and TNF-alpha mRNA levels were decreased in colonic T lymphocytes, and virtually no IL-2, IFN-gamma, TNF-alpha or TGF-beta positive cells were detected in basal lymphoid aggregates. However, scattered IL-10 positive cells were found here. Lamina propria outside the aggregates contained IL-10-, IFN-gamma, TNF-alpha and TGF-beta but not IL-2 positive cells. T cells of UC patients did not express IL-4 or IL-5. Taken, together the data suggest a generalized activation of IL-10 producing CD4+ T cells along the intestine of UC patients. The local environment seems to determine the biological consequences of elevated IL-10.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12974765      PMCID: PMC1808826          DOI: 10.1046/j.1365-2249.2003.02268.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  44 in total

Review 1.  Recent developments in the immunology of inflammatory bowel disease.

Authors:  T T MacDonald; G Monteleone; S L Pender
Journal:  Scand J Immunol       Date:  2000-01       Impact factor: 3.487

2.  Interleukin-10 (IL-10) augments allograft arterial disease: paradoxical effects of IL-10 in vivo.

Authors:  Y Furukawa; G Becker; J L Stinn; K Shimizu; P Libby; R N Mitchell
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

3.  Interleukin-10 increases Th1 cytokine production and cytotoxic potential in human papillomavirus-specific CD8(+) cytotoxic T lymphocytes.

Authors:  A D Santin; P L Hermonat; A Ravaggi; S Bellone; S Pecorelli; J J Roman; G P Parham; M J Cannon
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

Review 4.  Insights from mouse models of colitis.

Authors:  R Boismenu; Y Chen
Journal:  J Leukoc Biol       Date:  2000-03       Impact factor: 4.962

5.  Human intestinal mast cells produce IL-5 in vitro upon IgE receptor cross-linking and in vivo in the course of intestinal inflammatory disease.

Authors:  A Lorentz; S Schwengberg; C Mierke; M P Manns; S C Bischoff
Journal:  Eur J Immunol       Date:  1999-05       Impact factor: 5.532

6.  Characterisation of mucosal lymphoid aggregates in ulcerative colitis: immune cell phenotype and TcR-gammadelta expression.

Authors:  M M Yeung; S Melgar; V Baranov; A Oberg; A Danielsson; S Hammarström; M L Hammarström
Journal:  Gut       Date:  2000-08       Impact factor: 23.059

7.  Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group.

Authors:  S Schreiber; R N Fedorak; O H Nielsen; G Wild; C N Williams; S Nikolaus; M Jacyna; B A Lashner; A Gangl; P Rutgeerts; K Isaacs; S J van Deventer; J C Koningsberger; M Cohard; A LeBeaut; S B Hanauer
Journal:  Gastroenterology       Date:  2000-12       Impact factor: 22.682

8.  Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group.

Authors:  R N Fedorak; A Gangl; C O Elson; P Rutgeerts; S Schreiber; G Wild; S B Hanauer; A Kilian; M Cohard; A LeBeaut; B Feagan
Journal:  Gastroenterology       Date:  2000-12       Impact factor: 22.682

9.  An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation.

Authors:  C Asseman; S Mauze; M W Leach; R L Coffman; F Powrie
Journal:  J Exp Med       Date:  1999-10-04       Impact factor: 14.307

10.  Hapten-induced colitis is associated with colonic patch hypertrophy and T helper cell 2-type responses.

Authors:  T Dohi; K Fujihashi; P D Rennert; K Iwatani; H Kiyono; J R McGhee
Journal:  J Exp Med       Date:  1999-04-19       Impact factor: 14.307

View more
  52 in total

Review 1.  The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review.

Authors:  H Hanai; Y Takeda; M Eberhardson; R Gruber; A R Saniabadi; O Winqvist; R Lofberg
Journal:  Clin Exp Immunol       Date:  2010-11-16       Impact factor: 4.330

Review 2.  The role of mucosal T lymphocytes in regulating intestinal inflammation.

Authors:  Holm H Uhlig; Fiona Powrie
Journal:  Springer Semin Immunopathol       Date:  2005-06-15

3.  Pharmacological inhibition of GPR4 remediates intestinal inflammation in a mouse colitis model.

Authors:  Edward J Sanderlin; Mona Marie; Juraj Velcicky; Pius Loetscher; Li V Yang
Journal:  Eur J Pharmacol       Date:  2019-03-28       Impact factor: 4.432

4.  Involvement of 4-1BB (CD137)-4-1BBligand interaction in the modulation of CD4 T cell-mediated inflammatory colitis.

Authors:  P Maerten; B S Kwon; C Shen; G De Hertogh; P Cadot; D M A Bullens; L Overbergh; C Mathieu; G Van Assche; K Geboes; P Rutgeerts; J L Ceuppens
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

Review 5.  Gatekeepers of intestinal inflammation.

Authors:  Heather A Arnett; Joanne L Viney
Journal:  Inflamm Res       Date:  2010-01       Impact factor: 4.575

6.  Longitudinal analysis of inflammation and microbiota dynamics in a model of mild chronic dextran sulfate sodium-induced colitis in mice.

Authors:  Luigia De Fazio; Elena Cavazza; Enzo Spisni; Antonio Strillacci; Manuela Centanni; Marco Candela; Chiara Praticò; Massimo Campieri; Chiara Ricci; Maria Chiara Valerii
Journal:  World J Gastroenterol       Date:  2014-02-28       Impact factor: 5.742

7.  Patients with inflammatory bowel disease may have a transforming growth factor-beta-, interleukin (IL)-2- or IL-10-deficient state induced by intrinsic neutralizing antibodies.

Authors:  E C Ebert; A Panja; K M Das; R Praveen; X Geng; C Rezac; M Bajpai
Journal:  Clin Exp Immunol       Date:  2009-01       Impact factor: 4.330

8.  The expression profile of functional regulatory T cells, CD4+CD25high+/forkhead box protein P3+, in patients with ulcerative colitis during active and quiescent disease.

Authors:  K Kamikozuru; K Fukunaga; S Hirota; N Hida; Y Ohda; K Yoshida; Y Yokoyama; K Tozawa; K Kawa; M Iimuro; K Nagase; A R Saniabadi; S Nakamura; H Miwa; T Matsumoto
Journal:  Clin Exp Immunol       Date:  2009-03-09       Impact factor: 4.330

Review 9.  Role of cytokines in inflammatory bowel disease.

Authors:  Fausto Sanchez-Munoz; Aaron Dominguez-Lopez; Jesus-K Yamamoto-Furusho
Journal:  World J Gastroenterol       Date:  2008-07-21       Impact factor: 5.742

10.  Differential dose effects of recombinant IL-25 on the development of dextran sulfate sodium-induced colitis.

Authors:  S S Salum Mchenga; D Wang; F M Janneh; Y Feng; P Zhang; Z Li; C Lu
Journal:  Inflamm Res       Date:  2010-05-20       Impact factor: 4.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.